SICAV
China Evolution Equity Fund
A style agnostic, index unconstrained portfolio investing across shares of Chinese companies including A-shares, H-shares and US-listed Chinese stocks. We focus on areas of the market that may be overlooked by some investors.
ISIN LU2187417386
FACTSHEET
PHS
Wenli Zheng,
Portfolio Manager
Wenli Zheng is the portfolio manager of the China Evolution Equity Strategy for the International Equity Division. He also co-manages the Greater China portfolio for the International Discovery Strategy. Wenli started his investment career with T. Rowe Price in 2008 as a TMT analyst. Prior to this, Wenli was a strategic consultant with Capgemini.

Overview
Strategy
Fund Summary
Our approach focuses on uncovering stocks where change and growth are underappreciated or undiscovered. Leveraging our long history of investing in China, we seek to identify Chinese companies beyond the widely owned mega cap stocks that offer the long-term potential for durable or accelerating growth or a fundamental rerating.
Performance - Net of Fees

Team
Wenli Zheng,
Portfolio Manager
Wenli Zheng is the portfolio manager of the China Evolution Equity Strategy for the International Equity Division. He also co-manages the Greater China portfolio for the International Discovery Strategy. Wenli started his investment career with T. Rowe Price in 2008 as a TMT analyst. Prior to this, Wenli was a strategic consultant with Capgemini.
Portfolio Manager since
2020
Years at T. Rowe Price
12
Years investment experience
12
Charles Knudsen,
Portfolio Specialist
Chuck Knudsen is a portfolio specialist in the Equity Division of T. Rowe Price.
Years at
T. Rowe Price
15
Years investment experience
33
Robert Secker,
Portfolio Specialist
Robert Secker is a portfolio specialist representing the firm’s Asian and Chinese equity strategies to institutional clients, consultants, and prospects in the Equity Division.
Years at T. Rowe Price
11
Years investment experience
24

**Note: The prospectus (retail) is only applicable for the funds that are recognised schemes under the Securities and Futures Act 2001 (“SFA”). For the information memorandum on funds that are restricted schemes under the SFA, please contact us directly.

Benchmark Data Source: MSCI. MSCI and its affiliates and third-party sources and providers (collectively, “MSCI”) makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities and financial products. This report is not approved, reviewed, or produced by MSCI. Historical MSCI data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

Unless otherwise specified, all fund ratings, awards and data are as of 31-May-2022 and sourced from T. Rowe Price. 

Performance returns are calculated on a NAV-NAV basis, net of fees, with distributions reinvested. Returns for the current year performance is cumulative. Benchmark returns are shown with reinvestment of dividends after the deduction of withholding taxes.

The Excess Returns are shown as Fund % minus the benchmark.

Investment involves risk. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can fall as well as rise. You may get back less than the amounted invested. The performance returns are denominated in the share class dealing currency which can be a foreign currency and if so, US/SG dollar-based investors are exposed to fluctuations in the US/SG dollar/foreign currency exchange rate.

Before deciding to invest in the fund, you should read the offering document/prospectus (including its investment objectives, policies and any risk warnings) and the product highlights sheet which are available and may be obtained from this website.

T. Rowe Price Singapore Pte. Ltd. Is the appointed Singapore representative and agent for service of process in Singapore. SICAV refers to the T. Rowe Price Funds SICAV, a Luxembourg investment company with variable capital which is registered with Commission de Surveillance du Secteur Financier and which qualifies as an undertaking for collective investment in transferable securities (“UCITS”).

Daily performance data is based on the latest available NAV.  Performance returns for share classes less than 1 year old (and associated benchmarks) are cumulative rather than annualised.

Risk & Reward Data is calculated based on 5-year period or if such data is unavailable, it is calculated based on 3-year period. If the fund data history is shorter than 3-year period, Risk & Reward Data will not be shown.

The specific securities identified and described in this website do not represent all of the securities purchased, sold, or recommended for the sub-fund and no assumptions should be made that the securities identified and discussed were or will be profitable.

Where Top 10 Contributor and Detractor figures are shown (within the Holdings sections), these represent the Top 10 contributing/detracting securities by percentage of positive or negative contribution to performance as of 31-May-2022.

Where individual top contributor/detractor figures are shown, these are the largest contributors/detractors by percentage of fund size, out of the Top 10 contributors/detractors to fund performance as of 31-May-2022.

Calculation methodology of the contributors/detractors is available upon request. The specific securities identified and described do not represent all of the securities purchased, sold, or recommended for clients in the fund. A complete list of contributors/detractors for the period covered is available upon request.

Certain numbers in this website may not equal the stated totals due to rounding.